Dianthus Therapeutics Q3 2026 net loss widens 27% to $46.64 million
DNTH•Dianthus Therapeutics’ third-quarter 2026 net loss widened 27% year over year to $46.64 million. The company reported approximately $1.2 billion in cash, cash equivalents and investments, with projected runway into 2030.
1. Quarterly results
Dianthus Therapeutics’ third-quarter 2026 net loss widened 27% from a year earlier to $46.64 million. License revenue more than tripled to $1.21 million, while research and development expenses rose 40% to $45.6 million.
2. Cash and trial timing
Cash, cash equivalents and investments totaled approximately $1.2 billion at September 30, providing projected runway into 2030. Results from claseprubart’s Phase 2 MMN trial remain expected in December 2026, and a Phase 3 trial is planned for 2027.
